Last reviewed · How we verify
R-DA-EPOCH
R-DA-EPOCH is a rituximab-based chemotherapy regimen that combines the anti-CD20 monoclonal antibody rituximab with dose-adjusted etoposide, prednisone, oncovin (vincristine), cyclophosphamide, and doxorubicin (daunorubicin) to treat lymphoid malignancies.
R-DA-EPOCH is a rituximab-based chemotherapy regimen that combines the anti-CD20 monoclonal antibody rituximab with dose-adjusted etoposide, prednisone, oncovin (vincristine), cyclophosphamide, and doxorubicin (daunorubicin) to treat lymphoid malignancies. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL).
At a glance
| Generic name | R-DA-EPOCH |
|---|---|
| Sponsor | Fujian Medical University |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a modified version of the DA-EPOCH chemotherapy backbone, where rituximab (an anti-CD20 monoclonal antibody) is added to enhance immune-mediated tumor cell killing in CD20-positive B-cell lymphomas. The chemotherapy components work through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption, while rituximab provides targeted antibody-dependent cellular cytotoxicity and direct apoptosis induction.
Approved indications
- B-cell non-Hodgkin lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea and vomiting
- Mucositis
- Infusion-related reactions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (PHASE2)
- Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (PHASE1, PHASE2)
- Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (PHASE3)
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-DA-EPOCH CI brief — competitive landscape report
- R-DA-EPOCH updates RSS · CI watch RSS
- Fujian Medical University portfolio CI